The DOI matches its Crossref record; 89 of the 89 references it cites were found in a registry or an index.
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Open accessAbstract
Virotherapy is currently undergoing a renaissance, based on our improved understanding of virus biology and genetics and our better knowledge of many different types of cancer. Viruses can be reprogrammed into oncolytic vectors by combining three types of modification: targeting, arming and shielding. Targeting introduces multiple layers of cancer specificity and improves safety and efficacy; arming occurs through the expression of prodrug convertases and cytokines; and coating with polymers and the sequential usage of different envelopes or capsids provides shielding from the host immune response. Virus-based therapeutics are beginning to find their place in cancer clinical practice, in combination with chemotherapy and radiation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New functions for the matrix metalloproteinases in cancer progression
Egeblad, M., & Werb, Z. (2002) · Nature Reviews Cancer · doi:10.1038/nrc745 · Cited by 6,108
Darnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
HOW CELLS RESPOND TO INTERFERONS
Stark, G. R., Kerr, I. M., Williams, B. R. G., Silverman, R. H., & Schreiber, R. D. (1998) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.67.1.227 · Cited by 3,932
Antiviral Actions of Interferons
Samuel, C. E. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.778-809.2001 · Cited by 2,743
An Adenovirus Mutant That Replicates Selectively in p53- Deficient Human Tumor Cells
Bischoff, J. R., Kirn, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., et al. (1996) · Science · doi:10.1126/science.274.5286.373 · Cited by 1,760
Randall, R. E., & Goodbourn, S. (2008) · Journal of General Virology · doi:10.1099/vir.0.83391-0 · Cited by 1,571
A Road Map for Those Who Don't Know JAK-STAT
Aaronson, D. S., & Horvath, C. M. (2002) · Science · doi:10.1126/science.1071545 · Cited by 1,337
Khuri, F. R., Nemunaitis, J., Ganly, I., Arseneau, J., Tannock, I. F., Romel, L., Gore, M., Ironside, J., MacDougall, R. H., Heise, C., et al. (2000) · Nature Medicine · doi:10.1038/78638 · Cited by 1,101
SLAM (CDw150) is a cellular receptor for measles virus
Tatsuo, H., Ono, N., Tanaka, K., & Yanagi, Y. (2000) · Nature · doi:10.1038/35022579 · Cited by 1,054
The human CD46 molecule is a receptor for measles virus (Edmonston strain)
Dörig, R. E., Marcil, A., Chopra, A., & Richardson, C. D. (1993) · Cell · doi:10.1016/0092-8674(93)80071-l · Cited by 1,033
Markert, J. M., Medlock, M. D., Rabkin, S. D., Gillespie, G. Y., Todo, T., Hunter, W. D., Palmer, C. A., Feigenbaum, F., Tornatore, C., Tufaro, F., et al. (2000) · Gene Therapy · doi:10.1038/sj.gt.3301205 · Cited by 976
The plasminogen activation system in tumor growth, invasion, and metastasis
Andreasen, P. A., Egelund, R., & Petersen, H. H. (2000) · Cellular and Molecular Life Sciences (CMLS) · doi:10.1007/s000180050497 · Cited by 943
Human membrane cofactor protein (CD46) acts as a cellular receptor for measles virus
Naniche, D., Varior-Krishnan, G., Cervoni, F., Wild, T. F., Rossi, B., Rabourdin-Combe, C., & Gerlier, D. (1993) · Journal of Virology · doi:10.1128/jvi.67.10.6025-6032.1993 · Cited by 853
Stojdl, D. F., Lichty, B. D., tenOever, B. R., Paterson, J. M., Power, A. T., Knowles, S., Marius, R., Reynard, J., Poliquin, L., Atkins, H., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00241-1 · Cited by 842
A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo
Fueyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y.-X., Levin, V. A., Yung, W. K. A., & Kyritsis, A. P. (2000) · Oncogene · doi:10.1038/sj.onc.1203251 · Cited by 764
History of Oncolytic Viruses: Genesis to Genetic Engineering
Kelly, E., & Russell, S. J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300108 · Cited by 763
Engineering targeted viral vectors for gene therapy
Waehler, R., Russell, S. J., & Curiel, D. T. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2141 · Cited by 687
Jackson, R. J., Ramsay, A. J., Christensen, C. D., Beaton, S., Hall, D. F., & Ramshaw, I. A. (2001) · Journal of Virology · doi:10.1128/jvi.75.3.1205-1210.2001 · Cited by 565
Host cell proteases controlling virus pathogenicity
Klenk, H.-D., & Garten, W. (1994) · Trends in Microbiology · doi:10.1016/0966-842x(94)90123-6 · Cited by 466
Clinical trial results with oncolytic virotherapy: a century of promise, a decade of progress
Liu, T.-C., Galanis, E., & Kirn, D. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0736 · Cited by 450
An Effective AIDS Vaccine Based on Live Attenuated Vesicular Stomatitis Virus Recombinants
Rose, N. F., Marx, P. A., Luckay, A., Nixon, D. F., Moretto, W. J., Donahoe, S. M., Montefiori, D., Roberts, A., Buonocore, L., & Rose, J. K. (2001) · Cell · doi:10.1016/s0092-8674(01)00482-2 · Cited by 440
O'Riordan, C. R., Lachapelle, A., Delgado, C., Parkes, V., Wadsworth, S. C., Smith, A. E., & Francis, G. E. (1999) · Human Gene Therapy · doi:10.1089/10430349950018021 · Cited by 409
Morral, N., O’Neal, W., Rice, K., Leland, M., Kaplan, J., Piedra, P. A., Zhou, H., Parks, R. J., Velji, R., Aguilar-Córdova, E., et al. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12816 · Cited by 409
Barker, D., & Berk, A. J. (1987) · Virology · doi:10.1016/0042-6822(87)90441-7 · Cited by 385
Recent lessons in gene expression, cell cycle control, and cell biology from adenovirus
Berk, A. J. (2005) · Oncogene · doi:10.1038/sj.onc.1209040 · Cited by 377
Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity
O'Shea, C. C., Johnson, L., Bagus, B., Choi, S., Nicholas, C., Shen, A., Boyle, L., Pandey, K., Soria, C., Kunich, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.11.012 · Cited by 372
Ikeda, K., Ichikawa, T., Wakimoto, H., Silver, J. S., Deisboeck, T. S., Finkelstein, D., Harsh, G. R., Louis, D. N., Bartus, R. T., Hochberg, F. H., et al. (1999) · Nature Medicine · doi:10.1038/11320 · Cited by 339
Freytag, S. O., Rogulski, K. R., Paielli, D. L., Gilbert, J. D., & Kim, J. H. (1998) · Human Gene Therapy · doi:10.1089/hum.1998.9.9-1323 · Cited by 337
Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies
Fisher, K., Stallwood, Y., Green, N., Ulbrich, K., Mautner, V, & Seymour, L. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301389 · Cited by 316
mda-5, but not RIG-I, is a common target for paramyxovirus V proteins
Childs, K., Stock, N., Ross, C., Andrejeva, J., Hilton, L., Skinner, M., Randall, R., & Goodbourn, S. (2007) · Virology · doi:10.1016/j.virol.2006.09.023 · Cited by 301
p53 Status Does Not Determine Outcome of E1B 55-Kilodalton Mutant Adenovirus Lytic Infection
Goodrum, F. D., & Ornelles, D. A. (1998) · Journal of Virology · doi:10.1128/jvi.72.12.9479-9490.1998 · Cited by 289
STAT Protein Interference and Suppression of Cytokine Signal Transduction by Measles Virus V Protein
Palosaari, H., Parisien, J.-P., Rodriguez, J. J., Ulane, C. M., & Horvath, C. M. (2003) · Journal of Virology · doi:10.1128/jvi.77.13.7635-7644.2003 · Cited by 285
Freytag, S. O., Stricker, H. J., Pegg, J., Paielli, D. L., Pradhan, D. G., Peabody, J. O., de Peralta‐Venturina, M., Xia, X., Brown, S., Lü, M., et al. (2003) · PubMed · Cited by 271
Kambara, H., Okano, H., Chiocca, E. A., & Saeki, Y. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-3227 · Cited by 263
Crystal structure of measles virus hemagglutinin provides insight into effective vaccines
Hashiguchi, T., Kajikawa, M., Maita, N., Takeda, M., Kuroki, K., Sasaki, K., Kohda, D., Yanagi, Y., & Maenaka, K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707830104 · Cited by 259
Rescue and propagation of fully retargeted oncolytic measles viruses
Nakamura, T., Peng, K.-W., Harvey, M., Greiner, S., Lorimer, I. A. J., James, C. D., & Russell, S. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1060 · Cited by 252
Paramyxovirus membrane fusion: Lessons from the F and HN atomic structures
Lamb, R. A., Paterson, R. G., & Jardetzky, T. S. (2006) · Virology · doi:10.1016/j.virol.2005.09.007 · Cited by 250
Wong, L. H., Krauer, K. G., Hatzinisiriou, I., Estcourt, M. J., Hersey, P., Tam, N. D., Edmondson, S., Devenish, R. J., & Ralph, S. J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.45.28779 · Cited by 234
Mok, H., Palmer, D. J., Ng, P., & Barry, M. A. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.09.015 · Cited by 232
Self-citationCroyle, M. A., Chirmule, N., Zhang, Y., & Wilson, J. M. (2001) · Journal of Virology · doi:10.1128/jvi.75.10.4792-4801.2001 · Cited by 229
Current Advances and Future Challenges in Adenoviral Vector Biology and Targeting
Campos, S., & Barry, M. (2007) · Current Gene Therapy · doi:10.2174/156652307780859062 · Cited by 210
Self-citationDoyle, T. C., Burns, S. M., & Contag, C. H. (2004) · Cellular Microbiology · doi:10.1111/j.1462-5822.2004.00378.x · Cited by 209
Tumor-Specific, Replication-Competent Adenovirus Vectors Overexpressing the Adenovirus Death Protein
Doronin, K., Toth, K., Kuppuswamy, M., Ward, P., Tollefson, A. E., & Wold, W. S. M. (2000) · Journal of Virology · doi:10.1128/jvi.74.13.6147-6155.2000 · Cited by 206
Takeuchi, K., Kadota, S.-I., Takeda, M., Miyajima, N., & Nagata, K. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)00528-3 · Cited by 191
Systemic therapy of myeloma xenografts by an attenuated measles virus
Peng, K.-W., Ahmann, G. J., Pham, L., Greipp, P. R., Cattaneo, R., & Russell, S. J. (2001) · Blood · doi:10.1182/blood.v98.7.2002 · Cited by 181
Self-citationStem Cell Collection and Gene Transfer in Fanconi Anemia
Kelly, P. F., Radtke, S., Kalle, C. V., Balcik, B., Bohn, K., Mueller, R., Schuesler, T., Haren, M., Reeves, L., Cancelas, J. A., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300033 · Cited by 180
Chase, M., Chung, R. Y., & Chiocca, E. A. (1998) · Nature Biotechnology · doi:10.1038/nbt0598-444 · Cited by 178
Boviatsis, E., Park, J., Sena‐Esteves, M., Kramm, C. M., Chase, M., Efird, J. T., Wei, M., Breakefield, X. O., & Chiocca, E. A. (1994) · PubMed · Cited by 175
Tyrosine 110 in the measles virus phosphoprotein is required to block STAT1 phosphorylation
Devaux, P., von Messling, V., Songsungthong, W., Springfeld, C., & Cattaneo, R. (2007) · Virology · doi:10.1016/j.virol.2006.09.049 · Cited by 171
Self-citationSun, W. H., Pabon, C., Alsayed, Y., Huang, P. P., Jandeska, S., Uddin, S., Platanias, L. C., & Rosen, S. T. (1998) · Blood · doi:10.1182/blood.v91.2.570 · Cited by 169
Weapons of STAT destruction: Interferon evasion by paramyxovirus V proteins
Horvath, C. M. (2004) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.2004.04425.x · Cited by 159
Xiang, Z., Gao, G., Reyes‐Sandoval, A., Li, Y., Wilson, J. M., & Ertl, H. C. J. (2003) · Journal of Virology · doi:10.1128/jvi.77.20.10780-10789.2003 · Cited by 140
Ohno, S., Ono, N., Takeda, M., Takeuchi, K., & Yanagi, Y. (2004) · Journal of General Virology · doi:10.1099/vir.0.80308-0 · Cited by 130
Oncolytic measles viruses displaying a single-chain antibody against CD38, a myeloma cell marker
Peng, K.-W., Donovan, K. A., Schneider, U., Cattaneo, R., Lust, J. A., & Russell, S. J. (2003) · Blood · doi:10.1182/blood-2002-07-2195 · Cited by 124
Self-citationYamauchi, K., Yang, M., Hayashi, K., Jiang, P., Yamamoto, N., Tsuchiya, H., Tomita, K., Moossa, A. R., Bouvet, M., & Hoffman, R. M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3063 · Cited by 122
Sova, P., Ren, X.-W., Ni, S., Bernt, K. M., Mi, J., Kiviat, N., & Lieber, A. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2003.12.008 · Cited by 121
Conzelmann, K. (2005) · Journal of Virology · doi:10.1128/jvi.79.9.5241-5248.2005 · Cited by 117
Chung, R. Y., Saeki, Y., & Chiocca, E. A. (1999) · Journal of Virology · doi:10.1128/jvi.73.9.7556-7564.1999 · Cited by 115
Targeting adenoviral vectors using heterofunctional polyethylene glycol FGF2 conjugates
Lanciotti, J., Song, A., Doukas, J., Sosnowski, B. A., Pierce, G. F., Gregory, R. J., Wadsworth, S. C., & O’Riordan, C. R. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00139-4 · Cited by 114
Mechanisms of inhibition of the host interferon α/β-mediated antiviral responses by viruses
García‐Sastre, A. (2002) · Microbes and Infection · doi:10.1016/s1286-4579(02)01583-6 · Cited by 113
O’Shea, C. C., Soria, C. T., Bagus, B., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.009 · Cited by 112
Parks, R. J., Evelegh, C. M., & Graham, F. L. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300995 · Cited by 112
Targeting Human Medulloblastoma: Oncolytic Virotherapy with Myxoma Virus Is Enhanced by Rapamycin
Lun, X. Q., Zhou, H., Alain, T., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1214 · Cited by 110
Recombinant Measles Viruses Efficiently Entering Cells through Targeted Receptors
Schneider, U., Bullough, F. J., Vongpunsawad, S., Russell, S. J., & Cattaneo, R. (2000) · Journal of Virology · doi:10.1128/jvi.74.21.9928-9936.2000 · Cited by 110
Self-citationKim, E., Kim, J.-H., Shin, H. Y., Lee, H., Yang, J. M., Kim, J., Sohn, J., Kim, H., & Yun, C. (2003) · Human Gene Therapy · doi:10.1089/104303403769211637 · Cited by 109
Hemminki, A., Kanerva, A., Kremer, E. J., Bauerschmitz, G. J., Smith, B. F., Liu, B., Wang, M., Desmond, R. A., Keriel, A., Barnett, B. G., et al. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(02)00049-7 · Cited by 105
Genetically Targeted Adenovirus Vector Directed to CD40-Expressing Cells
Belousova, N., Korokhov, N., Krendelshchikova, V., Simonenko, V., Mikheeva, G., Triozzi, P. L., Aldrich, W. A., Banerjee, P. T., Gillies, S. D., Curiel, D. T., et al. (2003) · Journal of Virology · doi:10.1128/jvi.77.21.11367-11377.2003 · Cited by 104
Barton, K. N., Paielli, D. L., Zhang, Y., et al. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2005.10.005 · Cited by 92
Stanford, M. M., Barrett, J. W., Nazarian, S. H., Werden, S. J., & McFadden, G. (2006) · Journal of Virology · doi:10.1128/jvi.01408-06 · Cited by 90
Springfeld, C., von Messling, V., Frenzke, M. E., Ungerechts, G., Buchholz, C. J., & Cattaneo, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0538 · Cited by 90
Self-citationZhang, J. F., Hu, C., Geng, Y., Selm, J., Klein, S., Orazi, A., & Taylor, M. W. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.9.4513 · Cited by 88
Induced Apoptosis Supports Spread of Adenovirus Vectors in Tumors
Mi, J., Li, Z., Ni, S., Steinwaerder, D. S., & Lieber, A. (2001) · Human Gene Therapy · doi:10.1089/104303401750270995 · Cited by 83
Engineering Oncolytic Measles Virus to Circumvent the Intracellular Innate Immune Response
Haralambieva, I. H., Iankov, I. D., Hasegawa, K., et al. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300076 · Cited by 83
Vile, R. G., Ando, D. G., & Kirn, D. H. (2002) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700548 · Cited by 78
Hofherr, S. E., Mok, H. S., Gushiken, F. C., López, J. A., & Barry, M. A. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.0051 · Cited by 76
Self-citationZhou, G., & Roizman, B. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601258103 · Cited by 72
Hedley, S. J., der Maur, A. A., Hohn, S., Escher, D., Barberis, A., Glasgow, J. N., Douglas, J. T., Korokhov, N., & Curiel, D. T. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302603 · Cited by 66
Peng, K.-W., Vile, R. G., Cosset, F., & Russell, S. J. (1999) · Gene Therapy · doi:10.1038/sj.gt.3300982 · Cited by 66
Shashkova, E. V., Spencer, J. F., Wold, W. S. M., & Doronin, K. (2006) · Molecular Therapy · doi:10.1038/sj.mt.6300064 · Cited by 62
Self-citationE1A- and E1B-Double Mutant Replicating Adenovirus Elicits Enhanced Oncolytic and Antitumor Effects
Kim, J., Kim, J.-H., Choi, K., Kim, P.-H., & Yun, C. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.167 · Cited by 61
Cell carriers to deliver oncolytic viruses to sites of myeloma tumor growth
Munguia, A., Ota, T., Miest, T. S., & Russell, S. J. (2008) · Gene Therapy · doi:10.1038/gt.2008.45 · Cited by 57
Self-citationMolecular imaging of host-pathogen interactions in intact small animals
Piwnica-Worms, D. R., Schuster, D. P., & Garbow, J. R. (2004) · Cellular Microbiology · doi:10.1111/j.1462-5822.2004.00379.x · Cited by 51
Kinoh, H., Inoue, M., Washizawa, K., Yamamoto, T., Fujikawa, S., Tokusumi, Y., Iida, A., Nagai, Y., & Hasegawa, M. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302272 · Cited by 48
Dong, F., Wang, L., Davis, J. J., Hu, W., Zhang, L., Guo, W., Teraishi, F., Ji, L., & Fang, B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0244 · Cited by 42
Matin, S. F., Rackley, R. R., Sadhukhan, P. C., Kim, M. S., Novick, A. C., & Bandyopadhyay, S. K. (2001) · PubMed · Cited by 41
Kuppuswamy, M. N., Spencer, J. F., Doronin, K., Tollefson, A. E., Wold, W. S. M., & Tóth, K. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302581 · Cited by 39
Idema, S., Lamfers, M. L. M., van Beusechem, V. W., Noske, D. P., Heukelom, S., Moeniralm, S., Gerritsen, W. R., Vandertop, W. P., & Dirven, C. M. F. (2007) · The Journal of Gene Medicine · doi:10.1002/jgm.1113 · Cited by 38
Masking of Retroviral Envelope Functions by Oligomerizing Polypeptide Adaptors
Morling, F. J., Peng, K.-W., Cosset, F., et al. (1997) · Virology · doi:10.1006/viro.1997.8628 · Cited by 34
Kanai, R., Tomita, H., Shinoda, A., Takahashi, M., Goldman, S. A., Okano, H., Kawase, T., & Yazaki, T. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302636 · Cited by 27
Cited by
Oncolytic viruses: a new class of immunotherapy drugs
Kaufman, H. L., Kohlhapp, F. J., & Zloza, A. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4663 · Cited by 1,642
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Adherens junction protein nectin-4 is the epithelial receptor for measles virus
Mühlebach, M. D., Mateo, M., Sinn, P. L., Prüfer, S., Uhlig, K. M., Leonard, V. H. J., Navaratnarajah, C. K., Frenzke, M., Wong, X. X., Sawatsky, B., et al. (2011) · Nature · doi:10.1038/nature10639 · Cited by 602
Self-citationLipid-based systemic delivery of siRNA
Tseng, Y.-C., Mozumdar, S., & Huang, L. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.003 · Cited by 463
Oncolytic Viruses and Their Application to Cancer Immunotherapy
Chiocca, E. A., & Rabkin, S. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0015 · Cited by 408
Metadata
- Authors
- Cattaneo, R., Miest, T., Shashkova, E. V., & Barry, M. A.
- Venue
- Nature Reviews Microbiology
- Published
- 2008-07
- Volume
- 6
- Issue
- 7
- Pages
- 529-540
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- OpenAlex
- W1976892064
- Cited by
- 373
- References
- 89
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.